AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) has completed its previously announced public offering, raising $8.0 million in gross proceeds. The offering consisted of 2,000,000 shares of common stock (or pre-funded warrants) along with Class E and Class F warrants at a combined price of $4.00 per share.

The offering included Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with an exercise price of $4.00 per share. Maxim Group LLC served as the sole placement agent for this transaction, which was conducted under an effective S-1 registration statement.

Positive

• Raised $8.0 million in gross proceeds to strengthen balance sheet
• Warrants provide potential for additional future capital through exercises

Negative

• Potential dilution for existing shareholders from 2 million new shares
• Additional dilution possible from 4 million total warrant shares if exercised

News Market Reaction

-4.26%

4 alerts

-4.26% News Effect

+5.8% Peak Tracked

-$374K Valuation Impact

$8M Market Cap

0.0x Rel. Volume

On the day this news was published, AIM declined 4.26%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $374K from the company's valuation, bringing the market cap to $8M at that time.

Data tracked by StockTitan Argus on the day of publication.

OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to 2,000,000 shares of common stock, and Class F warrants to purchase up to 2,000,000 shares of common stock, at a combined public offering price of $4.00 per share (or $3.999 per pre-funded warrant) and accompanying warrants. The warrants have an exercise price of $4.00 per share, and were exercisable immediately upon issuance. The Class E warrants will expire on the fifth anniversary of the original issuance date, and the Class F warrants will expire on the eighteen-month anniversary of the original issuance date. Gross proceeds, before deducting placement agent fees and offering expenses, were approximately $8.0 million.

Maxim Group LLC acted as sole placement agent in connection with this offering.

The securities described above were being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-284443) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the "SEC") on July 28, 2025. Copies of the final prospectus relating to this offering have been filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16^th Floor, New York, NY 10022, at (212) 895-3745.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in the Registration Statement, the Company’s most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775

AIM@jtcir.com

FAQ

How much did AIM ImmunoTech (AIM) raise in its July 2025 public offering?

AIM ImmunoTech raised $8.0 million in gross proceeds through a public offering of common stock and warrants at $4.00 per share.

What is the structure of AIM ImmunoTech's July 2025 public offering?

The offering included 2 million shares of common stock (or pre-funded warrants), plus Class E warrants (5-year term) and Class F warrants (18-month term) to purchase up to 2 million shares each.

What is the exercise price of AIM's new warrants from the July 2025 offering?

Both the Class E and Class F warrants have an exercise price of $4.00 per share and were immediately exercisable upon issuance.

Who was the placement agent for AIM ImmunoTech's July 2025 public offering?

Maxim Group LLC acted as the sole placement agent for the offering.